Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 90 publications
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Journal: Dermatology and therapy
Published: February 08, 2024
Patient preferences for atopic dermatitis treatments: a discrete choice experiment.
Journal: The Journal of dermatological treatment
Published: June 23, 2023
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.
Journal: Dermatology (Basel, Switzerland)
Published: May 15, 2023
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
Journal: JAMA dermatology
Published: April 12, 2023
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).
Journal: Journal of the American Academy of Dermatology
Published: January 23, 2023
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Journal: The Journal of allergy and clinical immunology
Published: April 28, 2022
Assessment and Monitoring Challenges Among Patients With Moderate-to-Severe Atopic Dermatitis Across Fitzpatrick Skin Types: A Photographic Review and Case Series.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: March 23, 2022
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.
Journal: Journal of the American Academy of Dermatology
Published: March 02, 2022
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Journal: JAMA dermatology
Published: August 04, 2021
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
Journal: The Journal of allergy and clinical immunology
Published: March 30, 2021
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: December 11, 2020
A Man With New Subcutaneous Nodules: Answer.
Journal: The American Journal of dermatopathology
Published: July 01, 2020
Last Updated: 09/26/2026